GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » EV-to-EBIT

IO Biotech (IO Biotech) EV-to-EBIT : 0.28 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IO Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IO Biotech's Enterprise Value is $-24.75 Mil. IO Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-88.79 Mil. Therefore, IO Biotech's EV-to-EBIT for today is 0.28.

The historical rank and industry rank for IO Biotech's EV-to-EBIT or its related term are showing as below:

IOBT' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.3   Med: 0   Max: 1.9
Current: 0.28

During the past 5 years, the highest EV-to-EBIT of IO Biotech was 1.90. The lowest was -41.30. And the median was 0.00.

IOBT's EV-to-EBIT is ranked better than
85.55% of 429 companies
in the Biotechnology industry
Industry Median: 9.96 vs IOBT: 0.28

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IO Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $-1.69 Mil. IO Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-88.79 Mil. IO Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5,247.50%.


IO Biotech EV-to-EBIT Historical Data

The historical data trend for IO Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech EV-to-EBIT Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - 0.40 1.05 0.20

IO Biotech Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.70 0.88 0.20 0.02

Competitive Comparison of IO Biotech's EV-to-EBIT

For the Biotechnology subindustry, IO Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IO Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IO Biotech's EV-to-EBIT falls into.



IO Biotech EV-to-EBIT Calculation

IO Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-24.750/-88.79
=0.28

IO Biotech's current Enterprise Value is $-24.75 Mil.
IO Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IO Biotech  (NAS:IOBT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IO Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-88.79/-1.692043
=5,247.50 %

IO Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $-1.69 Mil.
IO Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IO Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of IO Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


IO Biotech (IO Biotech) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
Brian Burkavage officer: Chief Accounting Officer C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma 10 percent owner 24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith officer: General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad officer: Chief Medical Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan officer: Chief Financial Officer 38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier director 1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson director 1209 ORANGE STREET, WILMINGTON DE 19801

IO Biotech (IO Biotech) Headlines

From GuruFocus

IO Biotech Announces 2023 First-Quarter Results

By sperokesalga sperokesalga 05-11-2023

IO Biotech Announces Appointment of Devin Smith as General Counsel

By Stock market mentor Stock market mentor 01-23-2023

IO Biotech Provides Business Update

By Stock market mentor Stock market mentor 01-09-2023

IO Biotech to Participate in the 2022 BIO International Convention

By GuruFocusNews GuruFocusNews 07-06-2022